

**REMARKS**

Claims 15 to 46 are pending in this application. None of the claims have been allowed.

At page 2, of the Office Action, the Examiner set a Restriction Requirement, in which he identified 10 inventions (Groups), as follows:

"Group 1, claim(s) 1-14, drawn to a method of modulating androgen mediated function.

Group 2, claim(s) 15-20, 23-46, drawn to compounds, composition, method of making such composition, and a method of treating or preventing osteoporosis, osteopenia, and glucocorticoid-induced osteoporosis.

Group 3, claim(s) 15, 17, 18, 19, 21, 22, and 29-46, drawn to compounds, composition, method of making such composition, and a method of treating or preventing HIV-wasting.

Group 4, claim(s) 15, 17, 18, 19, 21, 22, and 29-46, drawn to compounds, composition, method of making such composition, and a method of treating or preventing cancer.

Group 5, claim(s) 15, 17, 18, 19, 21, 22, and 29-46, drawn to compounds, composition, method of making such composition, and a method of treating or preventing periodontal disease.

Group 6, claim(s) 15, 17, 18, 19, 21, 22, and 29-46, drawn to compounds, composition, method of making such composition, and a method of treating or preventing obesity.

Group 7, claim(s) 15, 17, 18, 19, 21, 22, and 29-46, drawn to compounds, composition, method of making such composition, and a method of treating or preventing anemia.

Group 8, claim(s) 15, 17, 18, 19, 21, 22, and 29-46, drawn to compounds, composition, method of making such composition, and a method of treating or preventing muscular dystrophies.

Group 9, claim(s) 19, 21, 22, and 29-46, drawn to compounds, composition, method of making such composition, and a method of treating or preventing autoimmune diseases.

Group 10, claim(s) 19, 21, 22, and 29-46, drawn to compounds, composition, method of making such composition, and a method of treating or preventing premature ovarian failure."


The week of April 21-25, the undersigned attorney exchanged voice mails with the Examiner concerning certain indications, including frailty, sarcopenia, and bone fracture, which were not included in any of the identified Groups. See for example Claim 32. The Examiner suggested that Applicants add or amend a claim that included the indications in question and that the Examiner would consider the matter.

As will be seen below, Applicants have elected Group II. However, consistent with the voice mail exchange, Applicants have amended Claim 1 to include additional indications which they believe should be a part of Group II. Applicants respectfully request the Examiner to reconsideration this matter.

At this time Applicants elect group II. Applicants traverse, only to the extent described immediately above.

At page 3 of the Office Action, the Examiner requires Applicants to identify a single species ("single compound") to which the claims shall be restricted if no generic is finally held to be allowable. The Examiner also requires Applicants to identify all of the claims readable on the elected species.

At this time Applicants elect the compound of Example 49: See Table 2, beginning at page 64:



The name for this compound is 17 $\beta$ -hydroxy-16-(pyrimidin-5-ylmethylidene)-4-methyl-4-aza-5 $\alpha$ -androst-1-en-3-one.

All of the pending claims, with the exception of Claims 38 to 41 are believed to be readable on this compound.

Having addressed the outstanding issues, Applicants respectfully request early examination and allowance of the claims. The Examiner is invited to contact the undersigned attorney at the telephone number provided below if such would advance the prosecution of this application.


Respectfully submitted,

By 

Curtis C. Panzer  
Reg. No. 33,752  
Attorney for Applicants

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-3199

Date: May 2, 2008



# P&T OFFICE ACKNOWLEDGEMENT

ATTORNEY	DATE
Curtis C. Panzer	5/2/2008
CASE NUMBER/	SERIAL NUMBER
20971P	10/501,640
DATE FILED	
July 15, 2004	
APPLICANT	
Dankulich, et al.	
EXPRESS MAIL NO.	

The Patent & Trademark Office acknowledges, and has stamped hereon, the date of the receipt of the items checked below:

- ☒ RESPONSE TO RESTRICTION REQUIREMENT
- ☐ APPEAL AND FEE
- ☐ BRIEF
- ☐ CERTIFICATE OF CORRECTION
- ☐ FINAL FEE
- ☐ LETTER
- ☐ INFORMATION DISCLOSURE STATEMENT
- ☐ PTO 1449 & REFERENCES
- ☐ PETITION FOR EXTENSION OF TIME & FEE
- ☐ INVITATION TO CORRECT
- ☐ DEMAND-CHAPTER II & FEE SHEET
- ☐ SEQUENCE STATEMENT
- ☐ SEQUENCE LISTING
- ☐ SEQUENCE DISKETTE